The epidermal growth factor receptor-L861Q mutation increases kinase activity without leading to enhanced sensitivity toward epidermal growth factor receptor kinase inhibitors.

Abstract excerpt

INTRODUCTION: Mutations in the epidermal growth factor receptor (EGFR) kinase domain such as EGFR-L858R and EGFR-G719S have been reported to activate the kinase and also sensitize a subset of patients with non-small cell lung cancer to EGFR kinase inhibitor treatment. Nevertheless, for other comm...

Topics

• Animals
• Blotting, Western
• Cell Proliferation
• Drug Resistance, Neoplasm
• ErbB Receptors
• Erlotinib Hydrochloride
• Gefitinib
• Humans
• Kidney
• Mice
• Mutation